| 1. |
Terasaki T, Semba Y, Sasaki K, Setoguchi K, Yamauchi T, Imanaga H, Nakao F, Hirabayashi S, Nogami J, Akashi K, Maeda T. , Genome-Wide CRISPR/Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis By Regulating MCL1 mRNA Cellular Localization. , American Society of Hematology Annual Meeting, San Diego, CA, 2023.12. |
| 2. |
SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Ogawa S, Akashi K, Maeda T., The XPO7/Npat Axis Inactivation Is a Therapeutic Vulnerability for TP53-Mutated AML. , American Society of Hematology Annual Meeting, San Diego, CA, 2023.12. |
| 3. |
Takahiro Maeda, Harnessing functional genomics to uncover potential targets for AML therapy. , 日本癌学会, 2024.10. |
| 4. |
Terasaki T, Semba Y, Sasaki K, Setoguchi K, Yamauchi T, Imanaga H, Nakao F, Hirabayashi S, Nogami J, Akashi K, Maeda T., Genome-Wide CRISPR-Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis by Regulating MCL1 mRNA Cellular Localization., FASEB Hematologic Malignancies Conference, 2023.08. |
| 5. |
Imanaga H, Semba Y, Sasaki K, Setoguchi K, Yamauchi T, Terasaki T, Nakao F, Hirabayashi S, Nogami J, Akashi K, Maeda T. , Autophagy Induction via mTORC1 Inhibition is an Essential Mechanism in Glucocorticoid-Mediated Cell Death in B-cell Precursor Acute Lymphoblastic Leukemia, FASEB Hematologic Malignancies Conference, 2023.08. |
| 6. |
Yuichiro Semba, Takahiro Maeda, The XPO7/NPAT axis as a potential therapeutic target for TP53-mutated AML., FASEB Hematologic Malignancies Conference, 2023.08. |
| 7. |
Takahiro Maeda, Identifying novel targets for AML therapy using functional genomic tools., BMT/HM Grand Rounds, Dana-Farber Cancer Institute., 2023.05. |
| 8. |
Takahiro Maeda, Identifying novel combination therapies for B-ALL harboring the IgH::CRLF2 rearrangement using functional genomics tools, European School of Haematology ALL 2023, Berlin, Germany, 2023.05. |
| 9. |
Hiroshi Imanaga, Yuichiro Semba, Kensuke Sasaki, Kiyoko Miyata, Takuji Yamauchi, Tatsuya Terasaki, Fumihiko Nakao, Shigeki Hirabayashi, Jumpei Nogami, Koichi Akashi, and Takahiro Maeda, Genome-wide CRISPR-Cas9 screens identify the GATOR1 complex as a critical regulator of glucocorticoid sensitivity in B-ALL, American Society of Hematology Annual Meeting, New Orleans, LA, 2022.12. |
| 10. |
Yuichiro Semba, Takuji Yamauchi, Fumihiko Nakao, Jumpei Nogami, Qiuming Yao, Matthew C. Canver, Luca Pinello, Daniel E. Bauer, Seishi Ogawa, Koichi Akashi and Takahiro Maeda, The XPO7/NPAT axis is a potential therapeutic target for TP53-mutated AML, American Society of Hematology Annual Meeting, New Orleans, LA, 2022.12. |
| 11. |
Sasaki K, Yamauchi T, Semba Y, Nogami J, Imanaga H, Terasaki T, Nakao F, Akahane K, Inukai T, Verhoeyen E, Akashi K and Maeda T, Genome-Wide CRISPR-Cas9 Screen Identifies Rationally Designed Combination Therapies Relevant for CRLF2-Rearranged Ph-like ALL, American Society of Hematology annual meeting, Atlanta, USA, 2021.12. |
| 12. |
Yamauchi T, Miyawaki K, Semba Y, Nakao F, Nogami J, Sugio T, Sasaki K, Canver MC, Osborne S, Pinello L, Taylor D, Bauer DR, Akashi K, Maeda T., PAICS, a de novo purine synthetic enzyme, is a novel target for AML therapy., American Society of Hematology annual meeting, Orland, USA, 2019.09. |
| 13. |
SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Akashi K, Maeda T., CRISPR-Cas9 screen identifies XPO7 as a potential therapeutic target for TP53-mutated AML., American Society of Hematology annual meeting, Orland, USA, 2019.09. |
| 14. |
Nakao F, Yamauchi T, SembaY, Nogami J, Akashi K and Maeda T., CRISPR-Cas9 screen identifies Me2, a mitochondrial malic enzyme, as a molecule relevant for MCL1 inhibitor resistance in AML. American Society of Hematology annual meeting,, American Society of Hematology annual meeting, Orland, USA, 2019.09. |
| 15. |
Sasaki K, Miyawaki K, Semba Y, Kato K, Nogami J, Sugio T, Miyamoto T, Ito Y, Nagafuji K, Maeda T, Akashi K. , A fast and accurate diagnostic method for Ph-like ALL using the nCounter system., American Society of Hematology annual meeting, Orland, USA, 2019.09. |
| 16. |
Miyawaki K, Yamauchi T, SugioT, Sasaki K, Miyoshi H, Osborne S, Taylor D, Ohshima K, Kato K, Maeda T, Akashi K. , PAICS inhibition is a potential therapeutic strategy for MYC-positive DLBCL., American Society of Hematology annual meeting, Orland, USA, 2019.09. |
| 17. |
Yamauchi T, Miyawaki K, Semba Y, Nakao F, Nogami J, Sugio T, Sasaki K, Canver MC, Osborne S, Pinello L, Taylor D, Bauer DR, Akashi K, Maeda T. , Genome-wide CRISPR screen identifies PAICS, and enzyme involved in de novo purine synthesis, as a potential target for AML therapy., SOHO 2019, 2019.09. |
| 18. |
Miyawaki K, Yamauchi T, SugioT, Sasaki K, Miyoshi H, Osborne S, Taylor D, Ohshima K, Kato K, Maeda T, Akashi K. , PAICS inhibition is a potential therapeutic strategy for MYC-positive aggressive DLBCL., SOHO 2019, 2019.09. |
| 19. |
SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Akashi K, Maeda T., CRISPR-Cas9 screen identifies XPO7 as a novel therapeutic target for TP53-mutated AML., SOHO 2019, 2019.09. |
| 20. |
Miyawaki K, Yamauchi T, SugioT, Sasaki K, Miyoshi H, Osborne S, Taylor D, Ohshima K, Kato K, Maeda T, Akashi K. , PAICS inhibition is a potential therapeutic strategy for MYC-positive aggressive DLBCL. , FASEB: The Hematologic Malignancies Conference., 2019.07. |
| 21. |
Yamauchi T, Miyawaki K, Semba Y, Nakao F, Nogami J, Sugio T, Sasaki K, Canver MC, Osborne S, Pinello L, Taylor D, Bauer DR, Akashi K, Maeda T. , Genome-wide CRISPR screen identifies PAICS, and enzyme involved in de novo purine synthesis, as a potential target for AML therapy., FASEB: The Hematologic Malignancies Conference., 2019.07. |
| 22. |
SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Akashi K, Maeda T. , CRISPR-Cas9 screen identifies XPO7 as a novel therapeutic target for TP53-mutated AML., FASEB: The Hematologic Malignancies Conference., 2019.07. |
| 23. |
Nakao F, Yamauchi T, SembaY, Nogami J, Akashi K and Maeda T. , CRISPR-Cas9 screen identifies Me2, a mitochondrial malic enzyme, as a molecule relevant for MCL1 inhibitor resistance. FASEB: The Hematologic Malignancies Conference., FASEB: The Hematologic Malignancies Conference., 2019.07. |
| 24. |
Sasaki K, Miyawaki K, Semba Y, Kato K, Nogami J, Sugio T, Miyamoto T, Ito Y, Nagafuji K, Maeda T, Akashi K., A fast and accurate diagnostic method for Ph-like ALL using the nCounter system., FASEB: The Hematologic Malignancies Conference., 2019.07. |
| 25. |
Takahiro Maeda, Leukemia-specific dependence on a nuclear pre-mRNA processing pathway regulated by the DCPS decapping enzyme, Novel insights into nuclear events in cancer, 2018.06. |
| 26. |
Takahiro Maeda, Genome-Wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway, American Society of Hematology Annual Meeting, 2017.12. |
| 27. |
Takahiro Maeda, Regulation of fetal hemoglobin expression by the LRF transcription factor, Japanese Society of Hematology, 2017.10. |
| 28. |
Yamauchi T, Masuda T, Canver MC, Seiler M, Semba Y, Shboul M, Al-Raqad M, Maeda M, Schoonenberg V.A.C., Cole MA, Trevino CM, Ishikawa Y, Yao Qiuming, Nakano M, Arai F, Orkin SH, Reversade B, Buonamici S, Pinello L, Akashi K, Bauer DE, Maeda T. , Targeting nuclear RNA metabolic pathways for the treatment of acute myeloid leukemia, Japanese Society of Hematology, 2017.10. |
| 29. |
Takahiro Maeda, Transcription factor LRF is a repressor of γ-globin expression., Gamma Globin Induction Translational Mini-Workshop. Children’s Hospital Boston, 2016.05. |
| 30. |
Takahiro Maeda, Identification of novel targets for AML therapy via a genome-wide CRISPR-Cas9 screen., 5th Cancer Stem Cell Symposium, 2016.11. |
| 31. |
Takahiro Maeda, Regulation of lympho-hematopoiesis by the transcription factor LRF/ZBTB7A, Japanese Society of Immunology, 2016.11. |
